Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia 3Hematologic Neoplasms 3Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Pancreatic Carcinoma 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Respiratory Tract Infections 1Respiratory Distress Syndrome 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Lymphoma, Mantle-Cell 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune-related Adverse Events 1

Interventions

siltuximab 3tocilizumab 1talquetamab 1obinutuzumab 1glofitamab 1axicabtagene ciloleucel 1Oxaliplatin 1Interleukin 1 Receptor Antagonist Protein 1Gemcitabine 1Gelsolin 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cytokine Release Syndrome × tocilizumab × Clear all
NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡